A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Adults who Require Regular Red Blood Cell Transfusions Due to Beta -Thalassemia

  • Kaplan, Zane (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA Reference Number: HREC/15/RAH/528
SSA Reference Number: SSA/16/MonH/176
Monash Health HREC Ref: 16249X
Effective start/end date20/05/1919/05/24


  • phase 3 study
  • treatment efficacy
  • clinical trial
  • thalassaemia